Cenexi turnaround delays
Cenexi's path to profitability may be delayed if new capacity ramp-up or commercial production timelines slip, or if lyophilizer issues recur.
high · management_commentaryGland Pharma Limited — Q2 FY25
Gland Pharma's Q2 FY25 consolidated revenue grew 2% YoY to INR 1,406 crore, with base business up 5% to INR 1,066 crore.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. revenue stagnation
U.S. revenue has been flat for three quarters despite multiple launches; growth may not materialize as expected if new contracts or Saudi offtake are delayed.
medium · analyst_questionCenexi gross margin volatility
Cenexi gross margin fell sharply to 69% due to product mix; may not normalize quickly if site-level issues persist.
medium · analyst_questionBiologics CDMO revenue uncertainty
Management declined to provide peak revenue potential for the Dr. Reddy's partnership, indicating early-stage and uncertain financial impact.
low · analyst_question